Albany Molecular Research (AMRI) : Permian Investment Partners Lp scooped up 1,541,073 additional shares in Albany Molecular Research during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 2,820,295 shares of Albany Molecular Research which is valued at $48,678,292.Albany Molecular Research makes up approximately 7.78% of Permian Investment Partners Lp’s portfolio.
Other Hedge Funds, Including , Parametric Portfolio Associates boosted its stake in AMRI in the latest quarter, The investment management firm added 3,980 additional shares and now holds a total of 23,063 shares of Albany Molecular Research which is valued at $401,527.Bessemer Group Inc boosted its stake in AMRI in the latest quarter, The investment management firm added 1,704 additional shares and now holds a total of 92,814 shares of Albany Molecular Research which is valued at $1,567,628. Albany Molecular Research makes up approx 0.01% of Bessemer Group Inc’s portfolio.Municipal Employees’ Retirement System Of Michigan reduced its stake in AMRI by selling 920 shares or 15.54% in the most recent quarter. The Hedge Fund company now holds 5,000 shares of AMRI which is valued at $78,300.Nationwide Fund Advisors boosted its stake in AMRI in the latest quarter, The investment management firm added 743 additional shares and now holds a total of 16,450 shares of Albany Molecular Research which is valued at $270,767.
Albany Molecular Research opened for trading at $17.36 and hit $17.43 on the upside on Monday, eventually ending the session at $17.36, with a gain of 0.12% or 0.02 points. The heightened volatility saw the trading volume jump to 1,44,921 shares. Company has a market cap of $745 M.
On the company’s financial health, Albany Molecular Research reported $0.17 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Nov 8, 2016. Analyst had a consensus of $0.13. The company had revenue of $151.70 million for the quarter, compared to analysts expectations of $160.75 million. The company’s revenue was up 45.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.12 EPS.
Albany Molecular Research Inc. is a global contract research and manufacturing organization providing drug discovery development and manufacturing services. The Company operates in three business segments: Discovery and Development Services (DDS) API and Drug Product. The Company offers a portfolio of services from target identification tools to investigational new drug (IND) enabling activities. The Company’s manufacturing facilities are situated in various locations in the United States Europe and Asia. The Company provides state-of-the-art facilities and solutions to deliver integrated pharmaceutical drug development programs and services including process research and development pre-formulation and formulation development good laboratory practices (GLP) bioanalytical and separation sciences.